OB-002 Significantly Reduces Bone Metastasis in a Murine Model of Breast Cancer

OTTAWA, Ontario, October 31, 2019 (Newswire.com) – Orion Biotechnology Canada, Ltd. today announced that OB-002 was able to significantly reduce bone metastasis in a murine model of breast cancer. The study was conducted in collaboration with ProQinase (Heidelberg, Germany; https://www.proqinase.com/). Female BALB/c mice received orthotopic implantation of 4T1-M3_Luc cells into the mammary fat pad. The 4T1 breast … Read moreOB-002 Significantly Reduces Bone Metastasis in a Murine Model of Breast Cancer

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com